Literature DB >> 15542757

Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.

Basalingappa L Hungund1, Balapal S Basavarajappa.   

Abstract

This review presents the remarkable research during the past several years indicating that some of the pharmacological and behavioral effects of alcohol, including alcohol drinking and alcohol-preferring behavior, are mediated through one of the most abundant neurochemical systems in the central nervous system, the endocannabinoid signaling system. The advances, with the discovery of specific receptors and the existence of naturally occurring cannabis-like substances in the mammalian system and brain, have helped in understanding the neurobiological basis for drugs of abuse, including alcoholism. The cDNA and genomic sequences encoding G-protein-coupled cannabinoid receptors (CB1 and CB2) from several species have now been cloned. This has facilitated discoveries of endogenous ligands (endocannabinoids). To date, two fatty acid derivatives characterized to be arachidonylethanolamide and 2-arachidonylglycerol have been isolated from both nervous and peripheral tissues. Both these compounds have been shown to mimic the pharmacological and behavioral effects of Delta9-tetrahydrocannabinol, the psychoactive component of marijuana. The involvement of the endocannabinoid signaling system in tolerance development to drugs of abuse, including alcohol, were unknown until recently. Studies from our laboratory demonstrated for the first time the downregulation of CB1 receptor function and its signal transduction by chronic alcohol. The observed downregulation of CB1 receptor binding and its signal transduction results from the persistent stimulation of receptors by the endogenous CB1 receptor agonists arachidonylethanolamide and 2-arachidonylglycerol, the synthesis of which is increased by chronic alcohol treatment. The deletion of CB1 receptor has recently been shown to block voluntary alcohol intake in mice, which is consistent with our previous findings where the DBA/2 mice known to avoid alcohol intake had significantly reduced brain CB1 receptor function. These findings suggest a role for the CB1 receptor gene in excessive alcohol drinking behavior and development of alcoholism. Ongoing investigations may lead to the development of potential therapeutic agents to modulate the endocannabinoid signaling system, which will be helpful for the treatment of alcoholism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542757     DOI: 10.1196/annals.1316.064

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  25 in total

1.  Consumption of medicines, alcohol, tobacco and cannabis among university students: a 2-year follow-up.

Authors:  Francisco Caamaño-Isorna; Nayara Mota; Alberto Crego; Montserrat Corral; Socorro Rodríguez Holguín; Fernando Cadaveira
Journal:  Int J Public Health       Date:  2010-10-27       Impact factor: 3.380

2.  Factors mediating alcohol craving and relapse: stress, compulsivity, and genetics.

Authors:  Zachary A Rodd; Kristin K Anstrom; Darin J Knapp; Ildiko Racz; Andreas Zimmer; Salvatore Serra; Richard L Bell; Donald J Woodward; George R Breese; Giancarlo Colombo
Journal:  Alcohol Clin Exp Res       Date:  2005-07       Impact factor: 3.455

Review 3.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

4.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

5.  β-Arrestin-2 inhibits preference for alcohol in mice and suppresses Akt signaling in the dorsal striatum.

Authors:  Haohong Li; Yezheng Tao; Li Ma; Xing Liu; Lan Ma
Journal:  Neurosci Bull       Date:  2013-07-09       Impact factor: 5.203

6.  Chronic alcohol produces neuroadaptations to prime dorsal striatal learning.

Authors:  Lauren DePoy; Rachel Daut; Jonathan L Brigman; Kathryn MacPherson; Nicole Crowley; Ozge Gunduz-Cinar; Charles L Pickens; Resat Cinar; Lisa M Saksida; George Kunos; David M Lovinger; Timothy J Bussey; Marguerite C Camp; Andrew Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

7.  Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference.

Authors:  Matthew S Powers; Gustavo D Barrenha; Nate S Mlinac; Eric L Barker; Julia A Chester
Journal:  Psychopharmacology (Berl)       Date:  2010-09-14       Impact factor: 4.530

8.  Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.

Authors:  Meenakshi Sabina Subbaraman; Jane Metrik; Deidre Patterson; Robert Swift
Journal:  Addiction       Date:  2017-01-10       Impact factor: 6.526

Review 9.  Drug addiction.

Authors:  Zuzana Justinova; Leigh V Panlilio; Steven R Goldberg
Journal:  Curr Top Behav Neurosci       Date:  2009

10.  Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.

Authors:  Lu-lu Yu; Xue-yi Wang; Mei Zhao; Yu Liu; Yan-qin Li; Fang-qiong Li; Xiaoyi Wang; Yan-xue Xue; Lin Lu
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.